This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is a Beat in Store for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Glaxo's (GSK) Vaccines and Respiratory segments are likely to have driven sales growth in the third quarter.
Lilly (LLY) Q3 Earnings Top Estimates, Sales Lag, Stock Down
by Zacks Equity Research
Eli Lilly's (LLY) Q3 earnings beat estimates while sales miss. Shares drop in pre-market trading.
5 High-Flying Corporate Giants Set to Beat on Q3 Earnings
by Nalak Das
Despite almost day-to-day market fluctuations, a few corporate behemoths surged in Wall Street. Some of these are set to beat earnings estimate in the ongoing reporting cycle.
Novartis (NVS) Q3 Earnings & Sales Beat Estimates, Up Y/Y
by Zacks Equity Research
Novartis (NVS) beats sales estimates in the third quarter of 2019, driven by robust performance of key drugs and increased contribution from new launches.
What's in the Cards for Sarepta (SRPT) This Earnings Season?
by Zacks Equity Research
Sarepta Therapeutics' (SRPT) third-quarter results are expected to reflect the impact of strong demand for Exondys 51. Regulatory update related to golodirsen is what investors are expected be focused on.
What's in the Cards for AstraZeneca (AZN) in Q3 Earnings?
by Zacks Equity Research
AstraZeneca's (AZN) third-quarter result is expected to reflect the impact of new drug sales.
Top Research Reports for Walmart, AstraZeneca & Broadcom
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Walmart (WMT), AstraZeneca (AZN) and Broadcom (AVGO).
AstraZeneca's Breast Cancer Candidate BLA Gets Priority Review
by Zacks Equity Research
AstraZeneca (AZN) announces acceptance of BLA seeking approval for trastuzumab deruxtecan in metastatic breast cancer by the FDA. The FDA also grants priority review.
Novartis' Jakavi Meets Primary Goal in Phase III for GVHD
by Zacks Equity Research
Novartis' (NVS) phase III REACH2 study on Jakavi for treating patients with steroid-refractory acute graft-versus-host disease meets the primary endpoint of superior overall response rate.
Should Value Investors Buy GlaxoSmithKline (GSK) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is GlaxoSmithKline plc (GSK) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (GSK) Outperforming Other Medical Stocks This Year?
The Zacks Analyst Blog Highlights: Novartis, J&J, Pfizer, Novo Nordisk and Glaxo
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novartis, J&J, Pfizer, Novo Nordisk and Glaxo
Emergent's Chikungunya Vaccine Candidate Gets EMA's PRIME Tag
by Zacks Equity Research
Emergent's (EBS) chikungunya vaccine candidate CHIKV VLP gains the PRIME status from the Committee for Medicinal Products for Human Use in Europe.
Pharma Stock Roundup: NVS' New Eye Drug Gets FDA Nod, NVO, GSK, PFE Sign Deals
by Kinjel Shah
FDA approves Novartis' (NVS) Beovu. J&J (JNJ) files sBLA for Stelara. Pfizer (PFE), Novo Nordisk (NVO) and Glaxo (GSK) announce collaboration deals.
Emergent's Vaccine Profile Boosts Sales Despite Stiff Rivalry
by Zacks Equity Research
Emergent's (EBS) vaccine portfolio holds great potential with the newly-acquired Narcan nasal spray progressing well. Severe rivalry remains a concern though.
Theravance Pipeline Strong, Dependence on Yupelri a Concern
by Zacks Equity Research
Theravance's (TBPH) newly-launched COPD drug Yupelri is witnessing a solid adoption while its pipeline programs are also progressing well. However, excessive reliance on Yupelri for revenues is a woe.
Thermo Fisher Closes API Site Buyout, Fortifies Pharma Unit
by Zacks Equity Research
Following the acquisition closure of GlaxoSmithKline's plant, Thermo Fisher (TMO) will continue to manufacture APIs for the same under a multi-year supply agreement.
The Zacks Analyst Blog Highlights: J&J, AstraZeneca, Roche, Glaxo and Merck
by Zacks Equity Research
The Zacks Analyst Blog Highlights: J&J, AstraZeneca, Roche, Glaxo and Merck
AstraZeneca's Fasenra Gets FDA Nod for Self-Administration
by Zacks Equity Research
The FDA approval of the self-administration option and auto-injector of AstraZeneca's (AZN) Fasenra is supported by data from the phase III GRECO study and the phase I AMES study
Pharma Stock Roundup: JNJ's Opioid Settlement, FDA Updates for AZN, GSK, MRK, RHHBY
by Kinjel Shah
J&J (JNJ) settles with two Ohio plaintiffs for $10 million. FDA updates for AstraZeneca (AZN), Merck (MRK) and others and ESMO presentations by big pharma companies in focus.
Gilead's Descovy HIV Regimen Gets FDA Nod for Label Expansion
by Zacks Equity Research
Gilead (GILD) obtains FDA approval for HIV treatment Descovy as a prevention option.
J&J Gets Breakthrough Therapy Tag for Prostate Cancer Drug
by Zacks Equity Research
J&J (JNJ) announces that the FDA has granted Breakthrough Therapy status to its PARP inhibitor, niraparib, for the treatment for advanced prostate cancer.
Here's Why You Should Add Thermo Fisher to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher's (TMO) performance.
AstraZeneca's Triple-Combo COPD Inhaler Gets CRL From FDA
by Zacks Equity Research
AstraZeneca (AZN) gets CRL from the FDA for PT010, its triple-combo inhaler to treat COPD.
Glaxo's Zejula Betters PFS in First-Line Ovarian Cancer Study
by Zacks Equity Research
Glaxo's (GSK) phase III study evaluating Zejula as a first-line maintenance therapy in patients with ovarian cancer significantly reduces risk of disease progression or death by 38%.